natgillin/translations-raw huggingface dataset:
Imatinib Actavis er indiceret til - behandling af voksne patienter med inoperabel dermatofibrosarkom protuberans (DFSP) og voksne patienter med residiverende og/eller metastaserende DFSP som ikke er tilgængelig for kirurgi. 
Imatinib Actavis is indicated for - the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
- Genopblussen (reaktivering) af hepatitis B-infektion, hvis du tidligere har haft hepatitis B (leverbetændelse type B). 
- Recurrence (reactivation) of Hepatitis B infection when you have had hepatitis B in the past (a liver infection).
Der blev set PDGFRomlejring hos 11 patienter, 9 af disse opnåede CHR og 1 PHR. 
In eleven patients PDGFR gene rearrangements was detected, 9 of them achieved a CHR and 1 PHR.
Imatinib var teratogent hos rotter ved administration under organgenese ved doser ≥100 mg/kg, ca. 
Imatinib was teratogenic in rats when administered during organogenesis at doses ≥ 100 mg/kg,
Imatinib er en protein-tyrosinkinasehæmmer, som potent hæmmer Bcr-Abl tyrosinkinasen in vitro, in vivo og på cellulært niveau. 
Imatinib is a protein-tyrosine kinase inhibitor which potently inhibits the Bcr-Abl tyrosine kinase at the in vitro, cellular and in vivo levels.
De 23 patienter som var inkluderet i registerstudiet, fik imatinib med en daglig mediandosis på 264 mg (dosisområde: 100 til 400 mg) med en median varighed på 7,2 år (behandlingstid 0,1 til 12,7 år). 
The 23 patients enrolled in this registry received imatinib at a median daily dose of 264 mg (range: 100 to 400 mg) for a median duration of 7.2 years (range 0.1 to 12.7 years).
- Føle sig svimmel eller svag. 
- Feeling dizzy or weak.
6-MP (75 mg/m2/dag, p.o.): dag 11-56 (tilbagehold 6-MP i de 6-10 dage med kraniebestråling med start dag 1 i cyklus 5. 
6-MP (75 mg/m2/day, PO): days 11-56 (Withhold 6-MP during the 6-10 days of cranial irradiation beginning on day 1 of Cycle 5.
Præbehandling med gentagne doser af rifampicin 600 mg efterfulgt af enkeltdosis imatinib 400 mg resulterede i fald i imatinib resulted in decrease in Cmax og AUC(0-∞) på mindst 54 % og 74 % af værdierne uden rifampicinbehandling. 
Pretreatment with multiple doses of rifampicin 600 mg followed by a single 400 mg dose of imatinib resulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the respective values without rifampicin treatment.
Imatinib metaboliseres primært i leveren, og kun 13 % udskilles via nyrerne. 
Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys.
I alt 51 børn med nydiagnosticeret og ubehandlet CML i kronisk fase blev inkluderet i en åben, multicenter, enkeltarm fase II undersøgelse. 
A total of 51 paediatric patients with newly diagnosed and untreated CML in chronic phase have been enrolled in an open-label, multicentre, single-arm phase II trial.
Patienter med mild, moderat eller svær nedsat leverfunktion bør gives den mindste anbefalede dosis på 400 mg daglig. 
Patients with mild, moderate or severe liver dysfunction should be given the minimum recommended dose of 400 mg daily.
Imatinib Actavis indeholder lecithin (soya) 
Imatinib Actavis contains lecithin (soya)
- Fortsæt derefter med den planlagte dosering. 
- Then continue with your normal schedule.
Der er meget begrænset erfaring hos børn med MDS/MPD, DFSP, og HES/CEL. 
There is very limited experience in children with MDS/MPD, DFSP, and HES/CEL.
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP BLISTERPAKNINGER 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTERS
Diverse bivirkninger, som for eksempel pleuraeksudat, ascites, lungeødem og hurtig vægtstigning med eller uden overfladiske ødemer, kan kollektivt betegnes som ”væskeretention”. 
Miscellaneous adverse reactions such as pleural effusion, ascites, pulmonary oedema and rapid weight gain with or without superficial oedema may be collectively described as “fluid retention”.
Incidensen af cytopeni hang imidlertid også tydeligt sammen med sygdomsstadiet, idet hyppighed af 3. eller 4. grads neutropeni (ANC <1,0 x 109/l) og thrombocytopenias (platelet count < 50 x 109/l) var 4-6 gange højere ved blastkrise og accelereret fase (59-64 % og 44-63 % for henholdsvis neutropeni og trombopeni) end ved sammenligning med nydiagnosticerede patienter med kronisk fase CML (16,7 % neutropeni og 8,9 % trombocytopeni). 
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC < 1.0 x 109/L) and thrombocytopenias (platelet count < 50 x 109/L) being between 4 and 6 times higher in blast crisis and accelerated phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
Palmoplantar erytrodysæstesi syndrom*, lichenoid keratosis*, lichen planus*, toksisk epidermal nekrolyse*, medikamentelt udslæt med eosinofili og systemiske symptomer (DRESS)* , pseudoporfyri* 
Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and systemic symptoms (DRESS)*, pseudoporphyria*
I dette studie indgik 7 patienter med MDS/MPD, som blev behandlet med 400 mg imatinib daglig. 
This study included 7 patients with MDS/MPD who were treated with imatinib 400 mg daily.
HES/CEL (ved 400 mg dosis) 
HES/CEL (at dose 400 mg)
Imatinib Actavis bruges til behandling af: 
Imatinib Actavis is a treatment for:
Når imatinib indtages i forbindelse med et måltid med høj fedtprocent, reduceres absorptionen af imatinib minimalt (11 %'s fald i Cmax og forlængelse af tmax med 1,5 time), med et lille fald i AUC (7,4 %) sammenlignet med fastende. 
When given with a high-fat meal, the rate of absorption of imatinib was minimally reduced (11% decrease in Cmax and prolongation of tmax by 1.5 h), with a small reduction in AUC (7.4%) compared to fasting conditions.
- børn med Ph+ CML i kronisk fase efter manglende effekt af alfa-interferonbehandling, eller i accelereret fase eller blastkrise. 
- paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
In vitro hæmmer imatinib O-glucuronidationen af paracetamol med en Ki-værdi på 58,5 mikromol/l. 
In vitro, imatinib inhibits paracetamol O-glucuronidation with Ki value of 58.5 micromol/L.
Meget almindelige (kan forekomme hos flere end 1 ud af 10 mennesker) eller almindelige (kan forekomme op til 1 ud af 10 mennesker): - Hurtig vægtøgning. 
Very common (may affect more than 1 in 10 people) or common (may affect up to 1 in 10 people): - Rapid weight gain.
Imatinib givet i kombination med kemoterapi-induktion (se Tabel 3) resulterede i en komplet hæmatologisk responsrate på 93% (147 ud af 158 evaluerbare patienter), og i en væsentlig cytogenetisk responsrate på 90% (19 ud af 21 evaluerbare patienter). 
Imatinib in combination with chemotherapy induction (see Table 3) resulted in a complete haematological response rate of 93% (147 out of 158 evaluable patients) and in a major cytogenetic response rate of 90% (19 out of 21 evaluable patients).
Denne kliniske effekt var efter 2 ugers behandling forbundet med en højere reduktion i bcr-abl transkriptionen hos de imatinibbehandlede patienter end i kemoterapiarmen (p=0,02). 
This clinical effect was associated with a higher reduction in bcrabl transcripts in the imatinib-treated patients than in the chemotherapy arm after 2 weeks of therapy (p=0.02).
Hvis der opstår stigninger i bilirubin >3 x IULN (institutional upper limit of normal) eller i levertransaminaser >5 x IULN, skal imatinib seponeres indtil bilirubinniveauerne er faldet til <1,5 x IULN og transaminaseniveauer til <2,5 x IULN. 
If elevations in bilirubin > 3 x institutional upper limit of normal (IULN) or in liver transaminases > 5 x IULN occur, imatinib should be withheld until bilirubin levels have returned to < 1.5 x IULN and transaminase levels to < 2.5 x IULN.
Cellulose, mikrokrystallinsk Copovidon 
Cellulose microcrystalline Copovidone
I undersøgelsen med patienter med inoperabel og/eller metastaserende GIST, oplevede 7 (5 %) af patienterne CTC grad 3-4: gastrointestinale blødninger (3 patienter), intra-tumorale blødninger (3 patienter) eller begge dele (1 patient). 
In the study in patients with unresectable and/or metastatic GIST, 7 (5%) patients experienced CTC grade 3/4 GI bleeds (3 patients), intra-tumoural bleeds (3 patients) or both (1 patient).
- Kraftig hovedpine, svækkelse eller lammelser af lemmer eller ansigt, talebesvær, pludseligt bevidsthedstab (tegn på problemer med nervesystemet såsom blødning eller hævelse i kranie/hjerne). 
- Severe headache, weakness or paralysis of limbs or face, difficulty speaking, sudden loss of consciousness (signs of nervous system problems such as bleeding or swelling in skull/brain).
Imatinibs sikkerhed og virkning hos børn under 18 år med MDS/MPD, DFSP og HES/CEL er ikke klarlagt i kliniske studier. 
The safety and efficacy of imatinib in children with MDS/MPD, DFSP and HES/CEL aged less than 18 years of age have not been established in clinical trials.
Der er begrænset erfaring hos børn og Ph-positiv ALL og meget begrænset erfaring med børn med MDS/MPD, DFSP og HES/CEL. 
There is limited experience in children with Ph-positive ALL and very limited experience in children with MDS/MPD, DFSP and HES/CEL.
Imatinib blev in vitro vist at være en kompetitiv hæmmer af markørsubstrater for CYP2C9, CYP2D6 og 
Imatinib was shown in vitro to be a competitive inhibitor of marker substrates for CYP2C9, CYP2D6 and CYP3A4/5.
Farmakoterapeutisk klassifikation: Antineoplastiske stoffer, protein-kinasehæmmer, ATC-kode: L01XE01 
Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitor, ATC code: L01XE01
Imatinibs effekt er hos voksne og børn er baseret på generelle hæmatologiske og cytogene responsrater og progressionsfri overlevelse ved CML, på hæmatologiske og cytogenetiske responsrater ved Ph+ ALL, MDS/MPD, på hæmatologiske responsrater ved HES/CEL, på objektive responsrater hos voksne med inoperabel og/eller metastaserende DFSP. 
In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP.
Histopatologiske undersøgelser af de afdøde rotter afslørede kardiomyopati (for begge køn), kronisk progressiv nefropati (hunkøn) og papillomaer på forhuden som hovedårsag til død eller begrundelse for aflivning. 
Histopathological examination of decedents revealed cardiomyopathy (both sexes), chronic progressive nephropathy (females) and preputial gland papilloma as principal causes of death or reasons for sacrifice.
Da imatinib blev givet som ”salvage therapy” til patienter, som ikke responderede eller som responderede dårligt på kemoterapi, opnåedes komplet hæmatologisk respons hos 9 (81,8%) ud af 11 patienter. 
When salvage therapy with imatinib was administered in patients who did not respond or who responded poorly to chemotherapy, it resulted in 9 patients (81.8%) out of 11 achieving a complete haematological response.
30 hårde kapsler 90 hårde kapsler 
30 hard capsules 90 hard capsules
Bærere af HBV, hvor behandling med (Imatinib Actavis) er nødvendig, skal overvåges tæt for tegn og symptomer på aktiv HBV-infektion i hele behandlingsperioden og i flere måneder efter behandlingsophør (se pkt. 
Carriers of HBV who require treatment with Imatinib Actavis should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section 4.8).
Til doser på 400 mg og derover (se anbefalede doser ovenfor) er en 400 mg tablet (ikke delelig) tilgængelig. 
For doses of 400 mg and above (see dosage recommendation above) a 400 mg tablet (not divisible) is available.
- Hævelse, som fx af anklerne eller omkring øjnene. 
- Swelling such as round your ankles or puffy eyes.
Baseret på den poolede farmakokinetiske populationsanalyse hos børn med hæmatologiske sygdomme (CML, Ph+ ALL eller andre hæmatologiske sygdomme behandlet med imatinib), stiger imatinib-clearance med stigende legemsoverflade. 
Based on pooled population pharmacokinetic analysis in paediatric patients with haematological disorders (CML, Ph+ALL, or other haematological disorders treated with imatinib), clearance of imatinib increases with increasing body surface area (BSA).
Tidligere gastrointestinale indgrebs påvirkning af lægemiddelabsorptionen er ikke undersøgt. 
The effect of prior gastrointestinal surgery on drug absorption has not been investigated.
- Kraftigt nedsat urinmængde, følelse af tørst (tegn på nyreproblemer). 
- Severely decreased urine output, feeling thirsty (signs of kidney problems).
Doser på 260 og 340 mg/m2/dag til børn gav samme optagelse som doser på henholdsvis 400 mg og 600 mg til voksne. 
Dosing in children at 260 and 340 mg/m2/day achieved the same exposure, respectively, as doses of 400 mg and 600 mg in adult patients.
3 På patientårsbasis blev kardielle hændelser, herunder hjerteinsufficiens, observeret oftere hos patienter med transformeret CML end hos patienter med kronisk CML. 
3 On a patient-year basis, cardiac events including congestive heart failure were more commonly observed in patients with transformed CML than in patients with chronic CML.
Ved en dosis på 60 mg/kg, havde hunrotterne et signifikant føtaltab efter implantation og et reduceret antal levende fostre. 
At a dose of 60 mg/kg, female rats had significant post implantation foetal loss and a reduced number of live foetuses.
Kontinuerlig daglig eksponering for imatinib tidligt i behandlingsforløbet i kombination med kemoterapi hos kohorte 5-patienter (n=50) forbedrede den 4-årige hændelsesfri overlevelse (EFS) sammenlignet med en historisk kontrolgruppe (n=120), der fik standard-kemoterapi uden imatinib (hhv. 69,6 % vs. 31,6 %). 
Continuous daily exposure to imatinib early in the course of treatment in combination with chemotherapy in cohort 5-patients (n=50) improved the 4-year event-free survival (EFS) compared to historical controls (n=120), who received standard chemotherapy without imatinib (69.6% vs. 31.6%, respectively).
Derudover angav investigatorene symptomatisk bedring af andre organdysfunktioner i kasuistikkerne. 
Additionally, improvements in symptomatology and other organ dysfunction abnormalities were reported by the investigators in the case reports.
- Bleghed, føle sig træt og stakåndet og have mørk urin (tegn på lavt antal røde blodceller). 
- Pale skin, feeling tired and breathlessness and having dark urine (signs of low levels of red blood cells).
Udskildning af fri imatinib er sandsynligvis sammenlignelig for patienter med nedsat nyrefunktion og dem med normal nyrefunktion, eftersom udskillelse via nyren kun udgør en mindre elimineringsvej for imatinib (se pkt. 
The free drug clearance of imatinib is probably similar between patients with renal impairment and those with normal renal function, since renal excretion represents only a minor elimination pathway for imatinib (see sections 4.2 and 4.4).
- Muskelkramper med feber, rød-brun urin, smerter eller svaghed i dine muskler (tegn på muskelproblemer). 
- Muscle spasms with a fever, red-brown urine, pain or weakness in your muscles (signs of muscle problems).
- voksne patienter med myelodysplastisk syndrom/myeloproliferative sygdomme (MDS/MPD) som er forbundet med platelet-derived growth factor receptor-omlejring (PDGFR-omlejring). 
- adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
Renal insufficiency: Patienter med nedsat nyrefunktion eller i dialyse bør gives den mindste anbefalede dosis på 400 mg daglig som startdosis. 
Renal insufficiency: Patients with renal dysfunction or on dialysis should be given the minimum recommended dose of 400 mg daily as starting dose.
- Hvis du er kvinde og er gravid eller planlægger at blive gravid, skal du være forsigtig, når du åbner kasplerne og håndterer indholdet for at undgå hud- og øjenkontakt eller indånding af pulveret. 
- If you are a woman who is pregnant or might get pregnant and are trying to open the capsules, you should handle the contents with caution in order to avoid skin-eye contact or inhalation.
Avaskulær nekrose/hoftenekrose*, væksthæmning hos børn* 
Avascular necrosis/hip necrosis*, growth retardation in children*
Imatinib Actavis hæmmer væksten af disse celler i en vis undergruppe af disse sygdomme. 
Imatinib Actavis inhibits the growth of these cells in a certain subtype of these diseases.
- Hedeture, kulderystelser eller natlig svedtendens. 
- Hot flushes, chills or night sweats.
I undersøgelsen med patienter med inoperabel og/eller metastaserende GIST rapporteredes anæmi grad 3 og 4 hos henholdsvis 5,4 % og 0,7 % af patienterne, hvilket kan hænge sammen med gastrointestinal eller intra-tumoral blødning, i hvert fald hos enkelte af patienterne. 
In the study in patients with unresectable and/or metastatic GIST, grade 3 and 4 anaemia was reported in 5.4% and 0.7% of patients, respectively, and may have been related to gastrointestinal or intratumoural bleeding in at least some of these patients.
Polyvinylalkohol, delvist hydroliseret Talcum 
Polyvinyl alchol part. hydrolised Talc
Imatinib Actavis hæmmer væksten af disse celler. 
Imatinib Actavis inhibits the growth of these cells.
- Muskelkramper eller led-, muskel- eller knoglesmerter mens du er i behandling med imatinib, eller efter du er stoppet med at tage imatinib. 
- Muscle cramps or joint, muscle or bone pain, during imatinib treatment or after you have stopped taking imatinib.
Ikke almindelige (kan forekomme hos op til 1 ud af 100 mennesker) eller sjældne (kan forekomme hos op til 1 ud af 1.000 mennesker): - Brystsmerter, uregelmæssig hjerterytme (tegn på hjerteproblemer). 
Uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people): - Chest pain, irregular heart rhythm (signs of heart problems).
5 Pleural effusion blev observeret oftere hos patienter med GIST og hos patienter med transformeret CML (CML-AP og CML-BC) end hos patienter med kronisk CML. 
5 Pleural effusion was reported more commonly in patients with GIST and in patients with transformed CML (CML-AP and CML-BC) than in patients with chronic CML.
Perikardit*, hjertetamponade* 
Pericarditis*, cardiac tamponade*
Det er en potent protein-tyrosinkinasehæmmer, der hæmmer aktiviteten af Bcr-Abl-tyrosinkinase (TK) såvel som adskillige TK-receptorer: Kit, receptoren for stamcellefaktoren (SCF) kodet for af c-kit proto-onkogenet, discoidin-domænereceptorerne (DDR1 og DDR2), receptoren for den kolonistimulerende faktor (CSF-1R) og receptorerne for trombocytafledte vækstfaktorer alfa og beta (PDGFR-alfa og PDGFR-beta). 
Imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the Bcr-Abl tyrosine kinase (TK), as well as several receptor TKs: Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta).
I dette studie blev 14 patienter med HES/CEL behandlet med 100 mg - 1.000 mg imatinib daglig. 
In this study, 14 patients with HES/CEL were treated with 100 mg to 1,000 mg of imatinib daily.
G-CSF (5 μg/kg, s.c.): dag 34-43 
G-CSF (5 μg/kg, SC): days 34-43
I et 2-års carcinogen studie i rotter resulterede administration af imatinib på 15, 30 og 60 mg/kg/dag i en signifikant reduktion i levetiden ved 60 mg/kg/dag for hanner og for hunner ved ≥30 mg/kg/dag. 
In the 2-year rat carcinogenicity study administration of imatinib at 15, 30 and 60 mg/kg/day resulted in a statistically significant reduction in the longevity of males at 60 mg/kg/day and females at ≥ 30 mg/kg/day.
1200 til 1600 mg (varighed varierer mellem 1 og 10 dage): Kvalme, opkastning, diarré, rødme, erytem, ødem, hævelse, træthed, muskelkramper, trombocytopeni, pancytopeni, abdominalsmerter, hovedpine, nedsat appetit. 
1200 to 1600 mg (duration varying between 1 to 10 days): Nausea, vomiting, diarrhoea, rash, erythema, oedema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite.
- Aktivt stof: imatinib (som mesilat). 
- The active substance is imatinib (as mesilate).
Total bilirubin: >1,5-3,0 ULNASAT: alt 
Total bilirubin: >1.5-3.0 ULN AST: any
Muskelspasmer og kramper, muskuloskeletale smerter herunder myalgi9, artralgi, knoglesmerter10 
Muscle spasm and cramps, musculoskeletal pain including myalgia9, arthralgia, bone pain10
Kvalme, diarré, opkast, dyspepsi, abdominalsmerter6 
Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain6
Pædiatriske patienter: I alt 26 pædiatriske patienter i alderen <18 år med enten CML i kronisk fase (n=11) eller CML i blastkrise eller Ph+ akut leukæmi (n=15) blev inkluderet i en fase I undersøgelse med dosiseskalering. 
Paediatric patients: A total of 26 paediatric patients of age < 18 years with either chronic phase CML (n=11) or CML in blast crisis or Ph+ acute leukaemias (n=15) were enrolled in a dose-escalation phase I trial.
Der er meget begrænset erfaring med imatinib hos patienter med MDS/MPD forbundet med PDGFR- omlejring (se pkt 5.1). 
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
Leverinsufficiens: Imatinib metaboliseres primært i leveren. 
Hepatic insufficiency: Imatinib is mainly metabolised through the liver.
CHR: I studie 0102 [ANC ≥ 1,5 x 109/l, trombocytter ≥ 100 x 109/l, ingen blaster i blodet, BM-blaster <5 % og ingen ekstramedullær sygdom]. 
CHR: In study 0102 [ANC ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, no blood blasts, BM blasts < 5% and no extramedullary disease]
Imatinib farmakokinetik er evalueret i dosisintervallet: 25-1.000 mg. Plasmafarmakokinetiske profiler blev analyseret på dag 1 og på enten dag 7 eller dag 28, hvor plasmakoncentrationerne havde nået steadystate. 
Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.
Anvendelse til børn: Der er ingen erfaring med behandling af børn under 2 år med CML og børn under 1 år med Ph+ ALL (se pkt. 
Paediatric use: There is no experience in children with CML below 2 years of age and with Ph+ALL below 1 year of age (see section 5.1).
Hyperbilirubinæmi, hepatitis, gulsot 
Hyperbilirubinaemia, hepatitis, jaundice
- Under behandlingen anbefales det, at kvinder som kan blive gravide, anvender effektiv beskyttelse mod graviditet. 
- Women who might become pregnant are advised to use effective contraception during treatment.
10 filmovertrukne tabletter 20 filmovertrukne tabletter 30 filmovertrukne tabletter 60 filmovertrukne tabletter 90 filmovertrukne tabletter 120 filmovertrukne tabletter 180 filmovertrukne tabletter 
10 film-coated tablets 20 film-coated tablets 30 film-coated tablets 60 film-coated tablets 90 film-coated tablets 120 film-coated tablets 180 film-coated tablets
- Symptomer på infektioner såsom feber, kraftige kulderystelser, ondt i halsen eller sår i munden. 
- Signs of infection such as fever, severe chills, sore throat or mouth ulcers.
Til patienter (børn) der ikke er i stand til at synke kapslerne, kan indholdet opløses i et glas almindeligt vand eller æblejuice. 
For patients (children) unable to swallow the capsules, their content may be diluted in a glass of either still water or apple juice.
Imatinib Actavis kan forårsage, at din krop begynder at ophobe væske (svær væskeretention). 
Imatinib Actavis may cause your body to retain water (severe fluid retention).
- Have kvalme med tab af appetitten, mørk urin, gul hud eller øjne (tegn på leverproblemer). 
- Feeling sick (nausea), with loss of appetite, dark-coloured urine, yellow skin or eyes (signs of liver problems).